Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Jan. 2024,
SanBio Co paid円0.00 Mil more to buy back shares than it received from issuing new shares.
It received円0.00 Mil from issuing more debt.
It paid円0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received円0.00 Mil from paying cash dividends to shareholders.
It received円0.00 Mil on other financial activities.
In all, SanBio Cospent円0.00 Mil on financial activities for the
three
months ended in Jan. 2024.
SanBio Co Cash Flow from Financing Historical Data
The historical data trend for SanBio Co's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
SanBio Co's Cash from Financing for the fiscal year that ended in Jan. 2024 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SanBio Co (TSE:4592) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
SanBio Co's issuance of stock for the
three
months ended in Jan. 2024 was 円0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
SanBio Co's repurchase of stock for the
three
months ended in Jan. 2024 was 円0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
SanBio Co's net issuance of debt for the
three
months ended in Jan. 2024 was 円0.00 Mil.
SanBio Co received円0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
SanBio Co's net issuance of preferred for the
three
months ended in Jan. 2024 was 円0.00 Mil.
SanBio Co paid円0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
SanBio Co's cash flow for dividends for the
three
months ended in Jan. 2024 was 円0.00 Mil.
SanBio Co received円0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
SanBio Co's other financing for the
three
months ended in Jan. 2024 was 円0.00 Mil.
SanBio Co received円0.00 Mil on other financial activities.
SanBio Co Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of SanBio Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4592 has been successfully added to your 